OLIPASS CORPORATION — Investor Relations & Filings
OLIPASS CORPORATION is a research and development company focused on creating RNA therapeutics. The company's core activities are centered on its proprietary OliPass Peptide Nucleic Acid (OPNA) platform. OPNA is a novel technology derived from Peptide Nucleic Acid (PNA) by introducing a cationic lipid moiety onto the nucleobase. This structural modification is designed to markedly improve cell permeability, a key challenge in nucleic acid-based drug delivery. The platform is optimized to induce exon skipping by specifically binding to target pre-mRNA inside the cell nucleus, enabling the discovery and development of new therapeutic candidates.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 반기또는분기매출액미달사실발생 | 2026-05-15 | Korean | |
| 기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행) | 2026-05-15 | Korean | |
| 분기보고서 (2026.03) | 2026-05-15 | Korean | |
| 기타경영사항(자율공시) | 2026-05-12 | Korean | |
| 주요사항보고서(회생절차개시신청) | 2026-05-07 | Korean | |
| 기타시장안내 (회생절차 개시신청 관련 시장안내) | 2026-05-07 | Korean |
Browse filings by year
9 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46368162 | 반기또는분기매출액미달사실발생 | 2026-05-15 | Korean | ||
| 46368161 | 기타시장안내 (상장적격성 실질심사 사유 추가 관련 절차 미진행) | 2026-05-15 | Korean | ||
| 46366895 | 분기보고서 (2026.03) | 2026-05-15 | Korean | ||
| 45195705 | 기타경영사항(자율공시) | 2026-05-12 | Korean | ||
| 42619619 | 주요사항보고서(회생절차개시신청) | 2026-05-07 | Korean | ||
| 42619588 | 기타시장안내 (회생절차 개시신청 관련 시장안내) | 2026-05-07 | Korean | ||
| 39045558 | [기재정정]투자판단관련주요경영사항 (OliPass PNA 플랫폼 기술 기반 희귀질환 치료제 및 면역항암제 관련 치료제 개발을 위한 Vanda 제약과 신약 공동연구개발 계약 체결) | 2026-04-30 | Korean | ||
| 39045553 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 39045545 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 39045536 | [기재정정]투자판단관련주요경영사항 (신약 공동연구개발 연구개발비 수령) | 2026-04-30 | Korean | ||
| 33669254 | 임원ㆍ주요주주특정증권등소유상황보고서 | 2026-04-07 | Korean | ||
| 33120351 | [기재정정]정기주주총회결과 | 2026-03-31 | Korean | ||
| 33120341 | [기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-31 | Korean | ||
| 33084964 | 사외이사의선임ㆍ해임또는중도퇴임에관한신고 | 2026-03-30 | Korean | ||
| 33084316 | 정기주주총회결과 | 2026-03-30 | Korean | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ACROBIOSYSTEMS CO.,LTD.
Provides recombinant proteins and reagents for life science…
|
301080 | CN | Professional, scientific and te… |
|
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's an…
|
ACW | AU | Professional, scientific and te… |
|
Active Biotech
Biotechnology company developing drugs for oncology and inf…
|
ACTI | SE | Professional, scientific and te… |
|
Adagene Inc.
Clinical-stage biotech developing antibody-based immunother…
|
ADAG | KY | Professional, scientific and te… |
|
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeuti…
|
1AD | AU | Professional, scientific and te… |
|
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for …
|
ADPT | US | Professional, scientific and te… |
|
Adeia Inc.
R&D company that licenses IP for the media, entertainment, …
|
ADEA | US | Professional, scientific and te… |
|
Aditxt, Inc.
Acquires, develops, and deploys health technologies to addr…
|
ADTX | US | Professional, scientific and te… |
|
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precis…
|
ADVB | US | Professional, scientific and te… |
|
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification o…
|
APC.H | CA | Professional, scientific and te… |
OLIPASS CORPORATION via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/17661/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=17661 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=17661 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=17661 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 17661}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for OLIPASS CORPORATION (id: 17661)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.